If we consider the significant finding in the blood transfusion rate, one hypothesis could be proposed: the combination of high-dose recombinant human erythropoietin and oral iron supplements may not only target the Hb levels, but also reduce anemia-related symptoms. Here, EPO is linked to anemia (phenotype).